XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investment in Altira (Details) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Jun. 01, 2021
Dec. 07, 2020
May 13, 2020
Jan. 31, 2021
Dec. 31, 2020
May 31, 2020
Jan. 31, 2022
Jul. 31, 2021
Jul. 31, 2020
Investment in Altira (Details) [Line Items]                  
Percentage of membership interest             33.333%    
Cost of investments             $ 7,000,000    
Impairment charges       $ 7,000,000          
Issuance of shares (in Shares)           4,000,000      
Membership interest         33.00%        
Business Combination [Member]                  
Investment in Altira (Details) [Line Items]                  
Investment in acquired description   the Company purchased an additional 33.333% of membership interests in Altira, pursuant to a Membership Interest Purchase Agreement (the “Second Altira Agreement”) between the Company and another Altira member, (the “Second Seller”). With this transaction, the Company now owns a right to an aggregate 66.666% of the membership interests in Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Second Seller sold his economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive an additional 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the Membership Interest consists of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 payable on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.              
Altira [Member]                  
Investment in Altira (Details) [Line Items]                  
Percentage of membership interest             33.333%    
Cost of investments             $ 4,000,000    
Contingent consideration             $ 6,000,000    
Impairment charge                 $ 4,000,000
Purchase Agreement [Member]                  
Investment in Altira (Details) [Line Items]                  
Purchase agreement, description     the First Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consisted of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each; 2) $3,000,000 payable on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceutical’s Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made to the First Seller, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten-day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.            
Class B Common Stock [Member]                  
Investment in Altira (Details) [Line Items]                  
Issuance of shares (in Shares) 48,859                
Class B Common Stock [Member] | Purchase Agreement [Member]                  
Investment in Altira (Details) [Line Items]                  
Issuance of shares (in Shares)               129,620  
Class B Common Stock [Member] | First Seller [Member]                  
Investment in Altira (Details) [Line Items]                  
Issuance of value               $ 3,500,000  
Class B Common Stock [Member] | Altira Second Seller [Member]                  
Investment in Altira (Details) [Line Items]                  
Issuance of shares (in Shares)               150,703  
Issuance of value               $ 5,000,000  
Cash payments               $ 2,000,000